- Home
- TENX vs INDP Comparison
TENX vs INDP Comparison
Compare TENX & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TENX
- INDP
- Stock Information
- Founded
- TENX 1967
- INDP 2000
- Country
- TENX United States
- INDP United States
- Employees
- TENX N/A
- INDP N/A
- Industry
- TENX Biotechnology: Pharmaceutical Preparations
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- TENX Health Care
- INDP Health Care
- Exchange
- TENX Nasdaq
- INDP Nasdaq
- Market Cap
- TENX 19.5M
- INDP 10.2M
- IPO Year
- TENX N/A
- INDP N/A
- Fundamental
- Price
- TENX $5.61
- INDP $0.94
- Analyst Decision
- TENX Strong Buy
- INDP Strong Buy
- Analyst Count
- TENX 4
- INDP 2
- Target Price
- TENX $20.67
- INDP $8.50
- AVG Volume (30 Days)
- TENX 67.9K
- INDP 25.8K
- Earning Date
- TENX 11-13-2024
- INDP 11-12-2024
- Dividend Yield
- TENX N/A
- INDP N/A
- EPS Growth
- TENX N/A
- INDP N/A
- EPS
- TENX N/A
- INDP N/A
- Revenue
- TENX N/A
- INDP N/A
- Revenue This Year
- TENX N/A
- INDP N/A
- Revenue Next Year
- TENX N/A
- INDP N/A
- P/E Ratio
- TENX N/A
- INDP N/A
- Revenue Growth
- TENX N/A
- INDP N/A
- 52 Week Low
- TENX $2.77
- INDP $0.84
- 52 Week High
- TENX $27.36
- INDP $3.10
- Technical
- Relative Strength Index (RSI)
- TENX 54.30
- INDP 40.51
- Support Level
- TENX $5.70
- INDP $0.94
- Resistance Level
- TENX $6.01
- INDP $1.01
- Average True Range (ATR)
- TENX 0.47
- INDP 0.06
- MACD
- TENX -0.08
- INDP 0.00
- Stochastic Oscillator
- TENX 12.15
- INDP 28.24
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.